Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Patent protection, ergo, patient protection
Companies that want to be successful in this shifting legal environment need to understand that intellectual property and patenting practices are essential in facilitating the competitive advantage and revenue returns as much as the value perceived by the patient.
Learn how to rise to challenges such as patent and regulatory concerns, legal matters and drug registration in new emerging markets. Are you asking why and how? Let's cut this Gordian knot.
Patent rights are extended around the world through the WTO's Agreement on Trade–Related Aspects of Intellectual Property Rights (TRIPS), but the high death toll from infectious but curable and preventable diseases: the cost plus the availability of drugs and medication; legal and tax related issues; as well as poor health infrastructure profoundly affect the results.
According to Forbes research from 2013, the pharma industry generates higher profit margins than any other industrial sector, spends more on marketing than on research & development and continues to grow while still paying million–dollar fines for malpractice, illegal or wrong means of promotion, etc… To quote Bill Gates, “It's fine to celebrate success but it is more important to heed the lessons of failure.”
So, what are the main factors?
Inventors. Recognize the original creation of human intellect (IP–Intellectual Property) and the legal rights given to the creator to protect his invention for a certain period of time (IPR–Intellectual Property Rights).
Governments. Take legal steps to minimize the negative impact of parallel trade. Help poorer countries through innovative public–private partnerships (as the previously mentioned entrepreneur is doing in Africa with his Bill & Melinda Gates Foundation, the largest private foundation in the world).
Patients. No mercenary, lose the “I” and as with patents, think of the same general requirements: usefulness, transparency and novelty. Provide it all.
Companies need to understand property protection not only as a step towards the return of investment. What goes around comes around. Drive innovation and be awe–inspiring.
How successful are you in creating patient value, innovation and inspiration, and at the same time generating ROI?
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.